Swapnil Parmar
Publications by Year
Research Areas
Cancer Genomics and Diagnostics, Advanced Breast Cancer Therapies, PARP inhibition in cancer therapy, Cancer Immunotherapy and Biomarkers, HER2/EGFR in Cancer Research
Most-Cited Works
- → An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer(2022)51 cited
- → Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics(2021)44 cited
- → Implementing a comprehensive translational oncology platform: from molecular testing to actionability(2018)43 cited
- → Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies(2021)24 cited
- → NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC).(2023)10 cited
- → A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer.(2019)8 cited
- → Implementing a comprehensive translational oncology platform: From molecular testing to actionability.(2018)5 cited
- → Abstract P4-12-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Abemaciclib in ER-Pos/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced or Metastatic Breast Cancer: TACTIVE-U Prelim Phase 1b Results(2025)4 cited
- → Abstract 3296: SMMART: Serial measurements of molecular and architectural responses to therapy(2018)3 cited
- → Enzyme replacement therapy with investigational rhGUS in an infant with non-immune hydrops fetalis and mucopolysaccharidosis type VII(2016)3 cited